ストックスクリーナーアプリを入手
3.48
1.46%
0.05
アフターアワーズ：
3.56
0.08
+2.30%
Eledon Pharmaceuticals Inc (ELDN) 最新ニュース
ELDN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
symbol__ Stock Quote Price and Forecast - CNN
Eledon Pharmaceuticals (ELDN) Announces Updated Results From Investigator-Initiated Trial Evaluating tegoprubart - Insider Monkey
10 Hot Biotech Stocks Under $5 to Buy - Insider Monkey
Eledon trial shows all 12 diabetes patients achieve insulin independence By Investing.com - Investing.com Australia
Eledon Pharmaceuticals (ELDN) Reports Promising Results for Tego - GuruFocus
Midday Stock Roundup: Eledon Up 4% on T1D Trial Results - Orange County Business Journal
Eledon Pharmaceuticals stock surges on diabetes trial results By Investing.com - Investing.com South Africa
Eledon Pharmaceuticals stock surges on diabetes trial results - Investing.com
Eledon Pharmaceuticals (ELDN) Reports Promising Results for Tegoprubart in T1D Trials - GuruFocus
Eledon trial shows all 12 diabetes patients achieve insulin independence - Investing.com
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine - The Manila Times
Eledon Pharmaceuticals Inc (ELDN) Stock Price, Quote, News & History - Benzinga
Eledon presents updated trial data on tegoprubart for type 1 diabetes at ADA 2026. - Pluang
Eledon trial results to be presented at diabetes conference By Investing.com - Investing.com South Africa
Eledon trial results to be presented at diabetes conference - Investing.com
Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions - The Manila Times
Type 1 diabetes islet transplant brings updated tegoprubart data to ADA - Stock Titan
Eledon Pharmaceuticals, Inc. - MLQ.ai
Is BillionToOne, Inc. (BLLN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Breakthrough in Diabetes Treatment with ELDN's New Drug Submissi - GuruFocus
EXCLUSIVE: NewcelX Advances Diabetes Therapy Toward Human Trials With FDA Pre-IND SubmissionEledon Pha - Benzinga
Stem cell therapy targeting a potential type 1 diabetes cure nears trials - Stock Titan
ELDN Technical Analysis & Stock Price Forecast - Intellectia AI
Eledon to present kidney transplant trial data at conference - Investing.com UK
Eledon to present kidney transplant trial data at conference By Investing.com - Investing.com Australia
Eledon to present new Phase 2 data on tegoprubart for kidney transplant rejection at June congress - Pluang
New kidney transplant rejection data from tegoprubart at ATC - Stock Titan
Eledon Pharmaceuticals to Present New Long-Term Data from - GlobeNewswire
LifeSci Capital Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $6 - Moomoo
TradingKey - TradingKey
BVF Group Discloses Convertible Stakes in Eledon (ELDN) — 9.99% Blockers - Stock Titan
Eledon Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $8.2, Implies 111% Upside - TradingView
LifeSci Capital Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Raises Target Price to $6 - Moomoo
Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights - The Manila Times
How Should Investors Value Eledon Pharmaceuticals (ELDN) After Q - GuruFocus
Eledon (ELDN) Advances in Tegoprubart Development with Key Miles - GuruFocus
Eledon Pharmaceuticals (ELDN) Reports Q1 Loss, Cash Reserves Dec - GuruFocus
Eledon Pharma Expects Cash, Cash Equivalents and Short-Term Investments to Fund Ops Into 2Q 2027 >ELDN - Moomoo
Eledon Pharmaceuticals 1Q Loss/Shr 33c >ELDN - Moomoo
Eledon Pharmaceuticals reports Q1 EPS (33c), consensus (23c) - TipRanks
Eledon Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Eledon Pharmaceuticals Q1 net loss widens on warrant liability loss - TradingView
Eledon Pharmaceuticals (ELDN) deepens Q1 2026 loss as R&D rises but cash totals $111M - Stock Titan
[8-K] Eledon Pharmaceuticals, Inc. Reports Material Event - Stock Titan
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):